Safety of isotretinoin to be reviewed by MHRA
An expert group of the Commission of Human Medicines is to be assembled to consider all data on the risk of psychiatric adverse reactions associated with isotretinoin (Roaccutane), according to a spokesman for the Medicines and Healthcare products Regulatory Agency. “It will also clarify how to best minimise that risk and what further research should be undertaken to achieve that. The date of this meeting has not yet been finalised but will likely [be] in the coming months,” he told The Pharmaceutical Journal.
The MHRA has kept the safety of isotretinoin under close review since it was licensed in the UK in 1983.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11138032
Recommended from Pharmaceutical Press
- Previous
- Next
Pharmaceutical Toxicology
Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.
£40.00Buy now
Traditional Medicine
Covers the major traditional medicine systems. Gives information on philosophy, practice, safety, evidence and examples.
£43.00Buy now
Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2017 (The Orange Guide)
Commonly known as the Orange Guide, this book is an essential reference for all involved in the manufacture or distribution of medicines in Europe.
£82.00Buy now
Rules and Guidance for Pharmaceutical Distributors 2017 (The Green Guide)
Essential guidance for distributors of medicines for human use in Europe, compiled by the MHRA.
£72.00Buy now
Print 
PDF
Have your say
For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.